AMLX - Amylyx Pharmaceuticals, Inc.

17.59
0.020   0.114%

Share volume: 814,579
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$17.57
0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 20%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.19%
1 Month
30.01%
3 Months
8.38%
6 Months
18.69%
1 Year
257.52%
2 Year
788.38%
Key data
Stock price
$17.59
P/E Ratio 
N/A
DAY RANGE
$17.16 - $17.77
EPS 
-$1.61
52 WEEK RANGE
$4.20 - $18.60
52 WEEK CHANGE
$247.63
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
110.537 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
2.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,181,994
AVERAGE 30 VOLUME 
$1,244,374
Company detail
CEO: Joshua B. Cohen
Region: US
Website: amylyx.com
Employees: 200
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.

Recent news